PF-04191834   Click here for help

GtoPdb Ligand ID: 9054

Synonyms: PF 4191834 | PF-4191834
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PF-4191834 is an orally available, novel, selective non-redox 5-lipoxygenase (ALOX5) inhibitor with potential antiinflammatory and analgesic activity [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 95.44
Molecular weight 393.15
XLogP 3.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cn1nccc1c1ccc(cc1)Sc1cccc(c1)C1(CCOCC1)C(=O)N
Isomeric SMILES Cn1nccc1c1ccc(cc1)Sc1cccc(c1)C1(CCOCC1)C(=O)N
InChI InChI=1S/C22H23N3O2S/c1-25-20(9-12-24-25)16-5-7-18(8-6-16)28-19-4-2-3-17(15-19)22(21(23)26)10-13-27-14-11-22/h2-9,12,15H,10-11,13-14H2,1H3,(H2,23,26)
InChI Key DVNQWYLVSNPCJZ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
A Phase 2 clinical trial evaluating the brochodilatory effect of a single dose of PF-04191834 in patients with asthma has been completed. A Phase 2 study in osteoarthritis was terminated.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
5-Lipoxygenase is an arachidonic acid-metabolizing enzyme producing leukotrienes and other proinflammatory lipid mediators with potent pathophysiological functions in asthma and other inflammatory diseases. Pharmacological inhibition would reduce proinflammatory mediator production, thereby reducing inflammation and associated pain.